Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
Serous tumors present more unfavorable anatomopathological characteristics but are associated with better prognosis than mucinous tumors. If mucinous BOT diagnosis is retained physicians should be aware that their aggressive potential is not negligible.
The addition of metabolic syndrome to traditional risk factors does not increase the prevalence of CAD determined by stress imaging.